NCT02755467 is a NA clinical trial of KTP laser in Spider Angioma, sponsored by Cutera Inc..

Who is sponsoring NCT02755467?

NCT02755467 is sponsored by Cutera Inc..

What drugs are being tested in NCT02755467?

Interventions in NCT02755467: KTP laser.

What condition does NCT02755467 study?

NCT02755467 studies Spider Angioma.

Is NCT02755467 still recruiting?

NCT02755467 is currently completed. Last updated 24 March 2023.

Are results published for NCT02755467?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-03-24 · How we verify

NCT02755467

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Evaluation of the Treatment of Spider Angioma

Completed NA Results posted Last updated 24 March 2023

What this trial tests

NA trial testing KTP laser in Spider Angioma in 22 participants. Completed in 4 April 2017.

Timeline

26 May 2016

Primary endpoint
13 January 2017

4 April 2017

Quick facts

Lead sponsor	Cutera Inc.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	22
Start date	26 May 2016
Primary completion	13 January 2017
Estimated completion	4 April 2017
Sites	1 location across United States

Drugs / interventions tested

KTP laser

Conditions studied

Spider Angioma — all drugs for Spider Angioma →

Sponsor

Cutera Inc.

Who can join

Adults 5 to 65, any sex, with Spider Angioma. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Physician's Global Assessment Scale for Improvement of Spider Angioma Primary · Four weeks post laser treatment.

Assessment of Baseline vs. 4 weeks post-final treatment for improvement of spider angiomas using the Physician's Global Assessment scale. High scores indicate better outcomes: 0\. None 1. Mild 2. Moderate 3. Significant 4. Very Significant 5. Complete Removal

Group	Value	95% CI
Laser Treatment	4.5	± 0.6

Adverse events — posted to ClinicalTrials.gov

Time frame: 4 weeks post final laser treatment. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Laser Treatment

Serious: 0/22 (0%)

Deaths: 0/22

Other adverse events (2 terms — click to expand)

Reaction	System	Laser Treatment
Purpura	Skin and subcutaneous tissue disorders	—
Erythema	Skin and subcutaneous tissue disorders	—

Data from ClinicalTrials.gov NCT02755467 adverse events section.

Sponsor's own description

To evaluate the safety and effectiveness of the laser treatment for the treatment of spider angiomas.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of KTP laser

Trials testing the same drug.

NCT06033352 — Potassium-titanyl Phosphate (KTP) Laser vs KTP Laser and Ivermectin Cream for Facial Rosacea · Phase 2 · completed

Other Cutera Inc. trials

Trials by the same sponsor.

NCT06469398 — A Post Market Device Study for the Treatment of Acne · NA · active not recruiting
NCT04695691 — A Device Study for the Treatment of Acne · NA · completed
NCT03782545 — Multi-Center Pilot Study of Cutera truSculpt Device · NA · completed
NCT03424148 — Open-label, Prospective, Multicenter Study to Evaluate the Cutera Excel V™ Laser and a Micro-Lens Array Attachment · NA · completed
NCT03424161 — Multi-Center, Clinical Evaluation of the Cutera Secret RF Device · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02755467 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cutera Inc.
Last refreshed: 24 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02755467.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing